Condition
High-Risk Melanoma
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Nivolumab Or Pembrolizumab
Research Leaders
16 sponsors active, led by Norrlands University Hospital
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Nivolumab Or Pembrolizumab1
- Imiquimod1
- Gp100209217 210m1
- Montanide Isa511
Active Sponsors
- Norrlands University Hospital1
- Falu Hospital1
- North Estonia Medical Centre Foundation1
- Karolinska University Hospital1
- University Hospital, Linkoeping1
Top Investigators
National Cancer Institute, National Institutes of Health
Uppsala University Hospital
Related Conditions
- Cutaneous Malignant Melanoma1